Temirov tested positive for the presence of Trimetazidine (TMZ), a drug used to treat heart failure and other cardiac conditions, in the class of hormone and metabolic modulators under the UFC ADP prohibited list. TMZ is prohibited at all times under the UFC ADP and was present in samples collected out-of-competition from Temirov on June 12, 2025, in Phuket, Thailand, and out-of-competition on July 4, 2025, also in Phuket, Thailand. Because Temirov was not notified of the June 12, 2025, adverse finding for TMZ until AFTER the collection on July 4, 2025, both adverse findings are combined into one violation under the UFC ADP rules.
Statement On Ramazonbek Temirov
